GSK enters agreement to acquire RAPT Therapeutics GSK plc (LSE NYSE: GSK) today announced that it has entered a definitive agreement to acquire RAPT Therapeutics (“RAPT”) (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon . . . About RAPT Therapeutics, Inc RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology
RAPT Therapeutics Announces $150 Million Private Placement RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with significant unmet needs in inflammatory diseases
Stock Information - RAPT Therapeutics, Inc. The Investor Relations website contains information about RAPT Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
Press Releases | RAPT Therapeutics, Inc. The Investor Relations website contains information about RAPT Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
SEC Filings | RAPT Therapeutics, Inc. The Investor Relations website contains information about RAPT Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
PowerPoint Presentation ABSTRACT BACKGROUND: FLX475 (tivumecirnon, or TIVU) is a selective CCR4 antagonist designed to block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment The FLX475-02 trial (NCT03674567) is a phase 1 2 study of FLX475 as monotherapy and in combination with pembrolizumab in subjects with advanced cancer Early encouraging data on the biologic effects